PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29212823-8 2018 Uptake studies under Na+-depletion and excess of taurocholate confirmed the presence of functional NTCP protein and indicated that NTCP, apart from OATP2B1, contributed substantially to the overall hepatic uptake of rosuvastatin in SCUHH. Rosuvastatin Calcium 216-228 solute carrier family 10 member 1 Homo sapiens 99-103 16697742-9 2006 Interestingly, the major human hepatic bile acid uptake transporter NTCP, but not rat Ntcp, also transported rosuvastatin. Rosuvastatin Calcium 109-121 solute carrier family 10 member 1 Homo sapiens 68-72 33051248-4 2021 To do so, we determined the uptake CL (CLint,uptake,cells ) of rosuvastatin (RSV) by TEC (OATPs/NTCP) and then scaled it to that in vivo by REF (the ratio of transporter abundance in human livers and TEC) determined by LC-MS/MS-based quantitative proteomics. Rosuvastatin Calcium 63-75 solute carrier family 10 member 1 Homo sapiens 96-100 33051248-4 2021 To do so, we determined the uptake CL (CLint,uptake,cells ) of rosuvastatin (RSV) by TEC (OATPs/NTCP) and then scaled it to that in vivo by REF (the ratio of transporter abundance in human livers and TEC) determined by LC-MS/MS-based quantitative proteomics. Rosuvastatin Calcium 77-80 solute carrier family 10 member 1 Homo sapiens 96-100 32101444-7 2020 Substrate-specific effects were observed for NTCP G191R, with TCA and rosuvastatin transport observed at 89% and 8% of wild type uptake, respectively. Rosuvastatin Calcium 70-82 solute carrier family 10 member 1 Homo sapiens 45-49 16697742-10 2006 Human hepatocyte studies suggested that NTCP alone accounted for approximately 35% of rosuvastatin uptake. Rosuvastatin Calcium 86-98 solute carrier family 10 member 1 Homo sapiens 40-44 16697742-13 2006 CONCLUSIONS: Multiple transporters mediate the overall hepatic uptake of rosuvastatin, and NTCP may be a heretofore unrecognized transporter important to the disposition of rosuvastatin and possibly other drugs/statins in clinical use. Rosuvastatin Calcium 73-85 solute carrier family 10 member 1 Homo sapiens 91-95 16697742-13 2006 CONCLUSIONS: Multiple transporters mediate the overall hepatic uptake of rosuvastatin, and NTCP may be a heretofore unrecognized transporter important to the disposition of rosuvastatin and possibly other drugs/statins in clinical use. Rosuvastatin Calcium 173-185 solute carrier family 10 member 1 Homo sapiens 91-95 29719454-2 2018 Rosuvastatin is known to be a substrate of OATP1B1, OATP1B3, NTCP, and BCRP transporters. Rosuvastatin Calcium 0-12 solute carrier family 10 member 1 Homo sapiens 61-65 29212823-8 2018 Uptake studies under Na+-depletion and excess of taurocholate confirmed the presence of functional NTCP protein and indicated that NTCP, apart from OATP2B1, contributed substantially to the overall hepatic uptake of rosuvastatin in SCUHH. Rosuvastatin Calcium 216-228 solute carrier family 10 member 1 Homo sapiens 131-135 21717139-5 2011 Rosuvastatin is a substrate of drug transporters such as human OATP1B1, OATP 1B3, OATP 1A2, BCRP and NTCP. Rosuvastatin Calcium 0-12 solute carrier family 10 member 1 Homo sapiens 101-105 25985569-0 2014 The effect of Na+/taurocholate cotransporting polypeptide (NTCP) c.800C > T polymorphism on rosuvastatin pharmacokinetics in Chinese healthy males. Rosuvastatin Calcium 95-107 solute carrier family 10 member 1 Homo sapiens 14-57 25985569-0 2014 The effect of Na+/taurocholate cotransporting polypeptide (NTCP) c.800C > T polymorphism on rosuvastatin pharmacokinetics in Chinese healthy males. Rosuvastatin Calcium 95-107 solute carrier family 10 member 1 Homo sapiens 59-63 25985569-1 2014 This study was designed to investigate the potential association between NTCP c.800C >T polymorphism and rosuvastatin pharmacokinetics in Chinese healthy males. Rosuvastatin Calcium 108-120 solute carrier family 10 member 1 Homo sapiens 73-77 25985569-7 2014 NTCP c.800C > T genetic polymorphism markedly effected rosuvastatin pharmacokinetics. Rosuvastatin Calcium 58-70 solute carrier family 10 member 1 Homo sapiens 0-4 25985569-12 2014 NTCP c.800C > T polymorphism play a critical role in the individual variability of rosuvastatin pharmacokinetics in Chinese healthy males after excluding the impact of OATP1B1 c.521T > C and BCRP c.421C > A polymorphisms. Rosuvastatin Calcium 86-98 solute carrier family 10 member 1 Homo sapiens 0-4 23881596-8 2014 Integrating prior in vitro information on the metabolism and transporter kinetics of rosuvastatin (organic-anion transporting polypeptides OATP1B1, OAT1B3 and OATP2B1, sodium-dependent taurocholate co-transporting polypeptide [NTCP] and breast cancer resistance protein [BCRP]) with one clinical dataset, the PBPK model was used to simulate the drug disposition of rosuvastatin for 11 reported studies that had not been used for development of the rosuvastatin model. Rosuvastatin Calcium 85-97 solute carrier family 10 member 1 Homo sapiens 227-231 23881596-10 2014 Subsequently, the validated model was used to investigate the impact of coadministration of cyclosporine (ciclosporin), an inhibitor of OATPs, BCRP and NTCP, on the exposure of rosuvastatin in healthy volunteers. Rosuvastatin Calcium 177-189 solute carrier family 10 member 1 Homo sapiens 152-156 27737931-1 2017 Rosuvastatin is a widely prescribed antihyperlipidemic which undergoes limited metabolism, but is an in vitro substrate of multiple transporters [organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, OATP1A2, OATP2B1, sodium-taurocholate cotransporting polypeptide, breast cancer resistance protein (BCRP), multidrug resistance protein 2 (MRP2), MRP4, organic anion transporter 3]. Rosuvastatin Calcium 0-12 solute carrier family 10 member 1 Homo sapiens 227-273 23996477-0 2013 Quantitative assessment of the contribution of sodium-dependent taurocholate co-transporting polypeptide (NTCP) to the hepatic uptake of rosuvastatin, pitavastatin and fluvastatin. Rosuvastatin Calcium 137-149 solute carrier family 10 member 1 Homo sapiens 106-110 23996477-3 2013 The present study revisited the interaction of statin drugs, including pitavastatin, fluvastatin and rosuvastatin, with the sodium-dependent taurocholate co-transporting polypeptide (NTCP) using gene transfected cell models. Rosuvastatin Calcium 101-113 solute carrier family 10 member 1 Homo sapiens 183-187 23930675-0 2013 Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients. Rosuvastatin Calcium 94-106 solute carrier family 10 member 1 Homo sapiens 44-51 21341987-5 2011 The stably transfected NTCP-A64T variant showed significantly decreased uptakes of taurocholate and rosuvastatin compared with wild-type NTCP. Rosuvastatin Calcium 100-112 solute carrier family 10 member 1 Homo sapiens 23-27 21341987-5 2011 The stably transfected NTCP-A64T variant showed significantly decreased uptakes of taurocholate and rosuvastatin compared with wild-type NTCP. Rosuvastatin Calcium 100-112 solute carrier family 10 member 1 Homo sapiens 137-141 21341987-6 2011 The decreased taurocholate uptake and increased rosuvastatin uptake were shown in the NTCP-S267F variant. Rosuvastatin Calcium 48-60 solute carrier family 10 member 1 Homo sapiens 86-90 20946088-6 2011 In contrast, NTCP*2 displayed greater transport of atorvastatin and rosuvastatin, compared with NTCP wild type. Rosuvastatin Calcium 68-80 solute carrier family 10 member 1 Homo sapiens 13-17 20946088-7 2011 Thus, the measurements of decreased rosuvastatin and atorvastatin transport by OATP1B1*15 were confounded by the presence of NTCP and its genetic variant, NTCP*2. Rosuvastatin Calcium 36-48 solute carrier family 10 member 1 Homo sapiens 125-129